Life Biosciences, headquartered in Boston, Massachusetts, United States, remains privately held in the biotechnology / epigenetic medicines space. The stock is not listed on any public market.
Life Biosciences has no published valuation.
Life Biosciences is a biotechnology company pioneering cellular rejuvenation using epigenetic restoration to reverse diseases of aging. Its Partial Epigenetic Reprogramming platform uses three transcription factors, OCT4, SOX2 and KLF4, delivered by adeno-associated virus vectors, to restore the epigenome of aged and injured cells to a younger, healthier state. Its lead candidate, ER-100, is in a Phase 1 trial for optic neuropathies including open-angle glaucoma and non-arteritic anterior ischemic optic neuropathy, conditions that damage retinal ganglion cells the eye cannot naturally regenerate.
Founded in 2017 by Harvard Medical School professor David Sinclair, Life Biosciences is based in Boston, Massachusetts.
Listed funds carry late-stage private names. A fund's latest schedule of investments shows whether it holds Life Biosciences.
Often trade at a premium or discount to NAV.
Platforms match existing holders with buyers. Life Biosciences availability at any moment is set by the holders.
High minimums, transfer approval, company right-of-first-refusal.
Valuations, rounds and IPO status for every company in the directory — Life Biosciences included.
No. Life Biosciences is a private company; its shares do not trade on a public exchange.
The closest biotechnology / epigenetic medicines peers are on the competitors page.
The routes section explains what is realistically available for a company at this stage.
Perpetual markets for stocks, gold, indices and pre-IPO names — settled on-chain, no wallet-to-exchange transfers.
